Company Name, Ticker, Customers, else..

Neubase Therapeutics inc (NASDAQ: NBSE)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Neubase Therapeutics Inc 's

Name: Neubase Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NBSE Sales vs. its Competitors Q3 2023

Comparing the current results to its competitors, Neubase Therapeutics Inc reported Revenue decrease in the 3 quarter 2023 year on year by 0 %, despite the revenue increase by the most of its competitors of 31.56 %, recorded in the same quarter.

• List of NBSE Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Neubase Therapeutics inc recorded a net loss, as well as most of its competitors.

<< NBSE Stock Performance Comparisons

<< See the full list of NBSE competitors

*Market share is calculated based on total revenue.

NBSE's Stock Performance relative to its Competitors

Publicly Traded Peers of Neubase Therapeutics inc

Wave Life Sciences Ltd
Share Performance

-20.70%

30 Days

Wave Life Sciences Ltd

Profile

Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.

More about Wave Life Sciences Ltd 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 828.275 mill.	$ 81.746 mill.	$ -202.473 mill.

Evelo Biosciences Inc
Share Performance

0.00%

Over The Past 5 Days

Evelo Biosciences Inc

Profile

Evelo Biosciences Inc is a biotechnology company focused on developing therapies for the treatment of various diseases. Their business model revolves around harnessing the potential of the body's own immune system through the development of monoclonal microbials. These microbials are designed to interact with the gut to elicit specific therapeutic effects, offering a novel approach to addressing medical conditions.

More about Evelo Biosciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.002 mill.	$ - mill.	$ -82.349 mill.

Enanta Pharmaceuticals Inc
Share Performance

-9.95%

This Quarter

Enanta Pharmaceuticals Inc

Profile

Enanta Pharmaceuticals Inc's business model focuses on the research, development, and commercialization of innovative small molecule drugs targeting viral infections and liver diseases.

More about Enanta Pharmaceuticals Inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 350.244 mill.	$ 65.258 mill.	$ -63.230 mill.

Cytokinetics Incorporated
Share Performance

-15.75%

This Quarter

Cytokinetics Incorporated

Profile

Cytokinetics Incorporated is a biopharmaceutical company with a business model centered around the discovery and development of novel muscle activators. They strive to improve the lives of patients with debilitating diseases by focusing on the development of potentially life-changing therapies. Cytokinetics aims to achieve commercial success by leveraging its expertise in muscle biology and utilizing strategic collaborations to bring their innovative therapies to market.

More about Cytokinetics Incorporated's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 8,810.136 mill.	$ 67.670 mill.	$ -894.002 mill.

Coya Therapeutics Inc
Share Performance

-2.93%

This Quarter

Coya Therapeutics Inc

Profile

Coya Therapeutics Inc's business model focuses on developing and providing therapeutic solutions for various medical conditions or diseases.

More about Coya Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 120.453 mill.	$ 8.019 mill.	$ -21.670 mill.

46 more competitors available

Sources: Neubase Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 19, 2026 5:19 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neubase Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.